We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Elisabet Manasanch MD

Elisabet E. Manasanch MD

Assistant Professor, Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas

Dr. Manasanch is an Associate Professor at the Department of Lymphoma/Myeloma at the University of Texas MD Anderson Cancer Center. She graduated with an MD degree from the University of Barcelona in 2005 and received an MHSc in Clinical Research from Duke University in 2014. She pursued internal medicine and medical oncology training at the University of Massachusetts and National Institutes of Health, respectively and is board-certified in both specialties. During her fellowship training at the National Institutes of Health, Dr. Manasanch focused on the research and treatment of plasma cell dyscrasias. In 2014, she was awarded the MD Anderson Cancer Center Clinical Innovator Award to study predictors of outcome after anti-CD38 antibody therapy in intermediate and high-risk smoldering multiple myeloma. She received the International Myeloma Foundation 2015 Brian D. Novis Research Award to implement minimal residual disease testing in multiple myeloma.  In 2016, she received the High Impact Clinical Research Support Program Award to support clinical research personnel funding. Currently, she leads the myeloma precursor disease program at MD Anderson with a focus in understanding early stages through new technology and applying immunotherapy to early treatment.

Disclosures

Dr. Manasanch has received research support from Sanofi, Quest Diagnostics, Novartis, JW Pharma, Merck; consultant fees from Takeda, Celgene, Sanofi, GSK, Janssen and Adaptive Biotechnologies.